FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963568295> ?p ?o ?g. }

• W1963568295 endingPage "206" @default.
• W1963568295 startingPage "199" @default.
• W1963568295 abstract "Erlotinib demonstrated significantly prolonged survival versus placebo in patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST is a phase IV trial initiated to provide erlotinib access to patients with advanced NSCLC. We report the interim analysis for patients enrolled in the TRUST trial in Italy.Eligible patients had stage IIIB/IV NSCLC and had failed or were unsuitable for chemotherapy. Erlotinib (150 mg/day orally) was given until disease progression or unacceptable toxicity. Patients were monitored monthly.At time of this analysis, data from 651 patients were available. Patient characteristics were: median age 66 years (range 30-87), male 69%, former or current smoker 71%, ECOG PS 0-1 81%, adenocarcinoma histology 52% and stage IV 82%. Erlotinib was administered as first-, second-, third- or other-line in 12, 45, 43 and <1% of patients, respectively. Response rate was 9%, with a disease-control rate of 63%. Median progression-free survival was 15 weeks and was longer in females (p<0.001), patients with adenocarcinoma (p=0.008), those with no smoking history (p<0.001) and patients who experienced skin toxicity (p<0.001). Safety data were available for 609 patients, 35% of whom had at least one adverse event (AE), but only 4% of patients discontinued treatment due to erlotinib-related AEs.This analysis of the Italian TRUST results confirms the activity and favourable safety profile of erlotinib in unselected patients with advanced NSCLC." @default.
• W1963568295 created "2016-06-24" @default.
• W1963568295 creator A5008403882 @default.
• W1963568295 creator A5026639715 @default.
• W1963568295 creator A5031031537 @default.
• W1963568295 creator A5032386417 @default.
• W1963568295 creator A5032477448 @default.
• W1963568295 creator A5033909956 @default.
• W1963568295 creator A5038581704 @default.
• W1963568295 creator A5042028913 @default.
• W1963568295 creator A5045384053 @default.
• W1963568295 creator A5067380273 @default.
• W1963568295 creator A5069937000 @default.
• W1963568295 creator A5071783009 @default.
• W1963568295 creator A5084773667 @default.
• W1963568295 creator A5086968828 @default.
• W1963568295 creator A5091084296 @default.
• W1963568295 date "2009-05-01" @default.
• W1963568295 modified "2023-10-16" @default.
• W1963568295 title "An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy" @default.
• W1963568295 cites W1968151389 @default.
• W1963568295 cites W1988442083 @default.
• W1963568295 cites W2014956732 @default.
• W1963568295 cites W2032573089 @default.
• W1963568295 cites W2043696829 @default.
• W1963568295 cites W2049484790 @default.
• W1963568295 cites W2101035251 @default.
• W1963568295 cites W2105832080 @default.
• W1963568295 cites W2120718661 @default.
• W1963568295 cites W2138297714 @default.
• W1963568295 cites W2146404049 @default.
• W1963568295 cites W2153477391 @default.
• W1963568295 cites W2157824687 @default.
• W1963568295 cites W2162439819 @default.
• W1963568295 cites W2169331014 @default.
• W1963568295 cites W2247225824 @default.
• W1963568295 doi "https://doi.org/10.1016/j.lungcan.2008.09.001" @default.
• W1963568295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18951651" @default.
• W1963568295 hasPublicationYear "2009" @default.
• W1963568295 type Work @default.
• W1963568295 sameAs 1963568295 @default.
• W1963568295 citedByCount "19" @default.
• W1963568295 countsByYear W19635682952012 @default.
• W1963568295 countsByYear W19635682952013 @default.
• W1963568295 countsByYear W19635682952014 @default.
• W1963568295 countsByYear W19635682952016 @default.
• W1963568295 countsByYear W19635682952018 @default.
• W1963568295 crossrefType "journal-article" @default.
• W1963568295 hasAuthorship W1963568295A5008403882 @default.
• W1963568295 hasAuthorship W1963568295A5026639715 @default.
• W1963568295 hasAuthorship W1963568295A5031031537 @default.
• W1963568295 hasAuthorship W1963568295A5032386417 @default.
• W1963568295 hasAuthorship W1963568295A5032477448 @default.
• W1963568295 hasAuthorship W1963568295A5033909956 @default.
• W1963568295 hasAuthorship W1963568295A5038581704 @default.
• W1963568295 hasAuthorship W1963568295A5042028913 @default.
• W1963568295 hasAuthorship W1963568295A5045384053 @default.
• W1963568295 hasAuthorship W1963568295A5067380273 @default.
• W1963568295 hasAuthorship W1963568295A5069937000 @default.
• W1963568295 hasAuthorship W1963568295A5071783009 @default.
• W1963568295 hasAuthorship W1963568295A5084773667 @default.
• W1963568295 hasAuthorship W1963568295A5086968828 @default.
• W1963568295 hasAuthorship W1963568295A5091084296 @default.
• W1963568295 hasConcept C121608353 @default.
• W1963568295 hasConcept C126322002 @default.
• W1963568295 hasConcept C143998085 @default.
• W1963568295 hasConcept C197934379 @default.
• W1963568295 hasConcept C2776256026 @default.
• W1963568295 hasConcept C2778087573 @default.
• W1963568295 hasConcept C2779438470 @default.
• W1963568295 hasConcept C2781182431 @default.
• W1963568295 hasConcept C535046627 @default.
• W1963568295 hasConcept C61943457 @default.
• W1963568295 hasConcept C71924100 @default.
• W1963568295 hasConceptScore W1963568295C121608353 @default.
• W1963568295 hasConceptScore W1963568295C126322002 @default.
• W1963568295 hasConceptScore W1963568295C143998085 @default.
• W1963568295 hasConceptScore W1963568295C197934379 @default.
• W1963568295 hasConceptScore W1963568295C2776256026 @default.
• W1963568295 hasConceptScore W1963568295C2778087573 @default.
• W1963568295 hasConceptScore W1963568295C2779438470 @default.
• W1963568295 hasConceptScore W1963568295C2781182431 @default.
• W1963568295 hasConceptScore W1963568295C535046627 @default.
• W1963568295 hasConceptScore W1963568295C61943457 @default.
• W1963568295 hasConceptScore W1963568295C71924100 @default.
• W1963568295 hasIssue "2" @default.
• W1963568295 hasLocation W19635682951 @default.
• W1963568295 hasLocation W19635682952 @default.
• W1963568295 hasOpenAccess W1963568295 @default.
• W1963568295 hasPrimaryLocation W19635682951 @default.
• W1963568295 hasRelatedWork W1602357875 @default.
• W1963568295 hasRelatedWork W1803443763 @default.
• W1963568295 hasRelatedWork W2015910003 @default.
• W1963568295 hasRelatedWork W2037082948 @default.
• W1963568295 hasRelatedWork W2056320953 @default.
• W1963568295 hasRelatedWork W2069129404 @default.
• W1963568295 hasRelatedWork W2069371231 @default.
• W1963568295 hasRelatedWork W2134035700 @default.

• next